The lowest standard dose of methotrexate for rheumatoid arthritis is 7.5 mg once per week. This is the usual starting dose for adults and the smallest amount typically prescribed to begin treatment. Some patients stay at this dose if their disease responds well, while others are escalated to higher doses over the following weeks.
Why 7.5 mg Is the Starting Point
Both the NHS and Mayo Clinic list 7.5 mg once weekly as the standard initial dose for adults with RA. From there, the dose can be gradually increased up to 20 mg per week in tablet form or 25 mg per week by injection. EULAR guidelines reference a target of around 25 mg weekly (roughly 0.3 mg per kilogram of body weight for an 80 kg person), but that’s the upper end of the range, not where most people begin.
A randomized trial comparing starting doses of 7.5 mg versus 15 mg per week found no significant difference in disease activity after 12 weeks when both groups had their doses escalated on a similar schedule. The rapid dose increases in both groups likely closed any gap between the two starting points, which suggests that beginning at 7.5 mg doesn’t put you at a disadvantage as long as your dose is adjusted appropriately if you’re not responding.
How Dose Escalation Typically Works
In clinical practice, rheumatologists reassess your response every few weeks. In one well-known trial protocol, patients started at 7.5 mg weekly. At week four, if any painful or swollen joints remained, the dose was bumped to 15 mg. At week eight, if the response was still inadequate, it went up to 20 mg. Once a stable dose controlled the disease, it stayed there.
This stepwise approach lets your body adjust gradually and helps your doctor find the lowest dose that actually controls your inflammation. Not everyone needs 20 or 25 mg. Some people do well at 10 or 15 mg long term.
Can You Go Below 7.5 mg?
Doses below 7.5 mg per week are not part of standard RA treatment guidelines. At that level, the drug is unlikely to suppress the immune activity driving joint inflammation effectively enough to prevent damage. Research on patients maintained at lower doses has found that about a quarter to a third experienced meaningful joint damage progression over two to three years, and even the study authors noted that the 7.5 mg starting dose was considered low.
The risk of undertreating RA is real. Persistent low-grade inflammation can erode cartilage and bone in ways that don’t fully reverse, even if treatment is later intensified. Factors like having a positive rheumatoid factor or elevated inflammatory markers increase this risk further.
Reducing Your Dose After Remission
If you’ve achieved stable remission, your rheumatologist may consider tapering your dose. A phase 3 trial in Germany tested this directly. Patients in remission were randomly assigned to continue their full dose, cut it in half, or cut it in half and then stop entirely after six months.
The results were clear: 81% of patients who continued their full dose stayed in remission at 12 months, compared to 59% of those who halved their dose and just 43% of those who stopped. Patients who tapered were three times more likely to flare than those who continued, and those who stopped were more than four times as likely to relapse. So while tapering is possible, it comes with a meaningful trade-off. Many rheumatologists will reduce the dose cautiously rather than eliminate it, aiming for the lowest amount that keeps the disease quiet.
EULAR guidelines note that when methotrexate is used in combination with a biologic medication, the methotrexate dose can sometimes be reduced to as low as 10 mg weekly and still provide a meaningful benefit over the biologic alone.
Oral Versus Injectable at Low Doses
At lower doses like 7.5 to 15 mg, the difference between oral tablets and subcutaneous injections is relatively modest. The gap widens at higher doses. Research published in The Journal of Rheumatology found that oral methotrexate delivers, on average, only about two-thirds of the drug into the bloodstream compared to the same dose given by injection. This variability is especially pronounced at doses of 25 mg and above.
If you’re on a low dose and tolerating tablets well, there’s generally no absorption-related reason to switch to injections. The injectable route becomes more relevant if your dose needs to go higher or if you experience significant nausea with oral tablets.
Folic Acid and Low-Dose Methotrexate
Regardless of where your dose lands, folic acid supplementation is a standard part of methotrexate treatment. Methotrexate works partly by interfering with how your body uses folate, and supplementing helps reduce common side effects like mouth sores, nausea, and liver enzyme elevations. EULAR guidelines specifically note that adequate folic acid supplementation should accompany methotrexate use, even at the lowest doses. Most patients take 5 mg of folic acid on a non-methotrexate day each week, though your prescribing doctor will specify the amount and timing.